AG真人官方

Form 144 notice for proposed sale of securities under Rule 144. The filing shows 11,000 shares of common stock to be sold through Morgan Stanley Smith Barney LLC on 08/21/2025 with an aggregate market value of $3,396,248.90 and the issuer reported 45,226,262 shares outstanding. The securities were acquired on 08/21/2025 by stock option exercise and payment was in cash. The filing also lists multiple recent sales by Paul Mahon totaling 66,000 shares in the past three months. The notice includes the standard signature representation that the seller has no undisclosed material adverse information.

Paul A. Mahon, EVP & General Counsel of United Therapeutics (UTHR), exercised 11,000 stock options at an exercise price of $135.42 on 08/07/2025 and sold the resulting 11,000 shares pursuant to a pre-arranged 10b5-1 plan entered December 24, 2024. The sales were executed in multiple tranches with reported weighted-average prices ranging from $297.4924 to $303.45, and explanatory notes list the trade-price ranges for each tranche. After these transactions Mahon beneficially owned 36,781 common shares and continued to hold 88,000 exercisable stock options. The Form 4 reports the option exercise, the subsequent share disposals, and post-transaction holdings.

United Therapeutics Corp. (UTHR) has filed a Form S-8 to register 950,000 additional common shares (par $0.01) for issuance under its Amended & Restated 2015 Stock Incentive Plan. The company relies on General Instruction E, incorporating eight prior S-8 filings that together registered 13,820,000 shares; cumulative authorization for the plan now totals 14,770,000 shares. UTHR is incorporated in Delaware, qualifies as a large accelerated filer, and lists its principal executive offices in Silver Spring, MD.

The filing, signed by Chair & CEO Martine A. Rothblatt on 30 July 2025, contains standard exhibits such as the counsel opinion, auditor consent, and plan document. No financial statements, earnings data, or new corporate events are included; the registration strictly facilitates future equity compensation grants.

United Therapeutics (UTHR) Form 4: EVP & General Counsel Paul A. Mahon exercised 11,000 stock options at an exercise price of $135.42 on 07/24/2025, converting them into common shares. The same day, he disposed of the entire 11,000-share lot through three open-market sales executed under a pre-arranged Rule 10b5-1 plan at weighted-average prices of $303.31, $304.25 and $305.14, generating gross proceeds of roughly $3.3 million and a spread of about $168 per share over the strike price.

Following the transactions Mahon retains 36,781 shares of common stock held directly and continues to hold 99,000 unexercised options (same grant, expiring 03/15/2027). No other classes of securities were affected.

The filing represents routine insider activity disclosed within two business days and does not alter company guidance or fundamentals. Investors often monitor insider sales for sentiment signals; however, the use of a 10b5-1 plan and the retention of a sizable equity stake temper any negative inference.